Low-Grade Glioma Global Market Report 2025

Description

Low-grade gliomas are a type of brain tumor that originates from glial cells, which support and insulate nerve cells in the brain. These tumors are characterized by slow growth and generally less aggressive behavior than high-grade gliomas, though they can still cause significant neurological symptoms and may require treatment.

The primary drug types for low-grade glioma include trametinib, dabrafenib, ivosidenib, and mirdametinib. Trametinib is a medication that treats certain cancers by inhibiting the MEK1/2 proteins involved in cancer cell growth. Treatment for low-grade glioma typically involves a combination of surgery, chemotherapy, and radiation. Medications are administered through various routes, including oral and topical delivery, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The low-grade glioma market research report is one of a series of new reports from The Business Research Company that provides low-grade glioma market statistics, including the low-grade glioma industry global market size, regional shares, competitors with the low-grade glioma market share, detailed low-grade glioma market segments, market trends, and opportunities, and any further data you may need to thrive in the low-grade glioma industry. This low-grade glioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The low-grade glioma market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.47 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to growth in awareness of brain tumors, increased funding in oncology spurred research, an increase in orphan drug designations, the expansion of telemedicine, and an increase in healthcare access.

The low-grade glioma market size is expected to see strong growth in the next few years. It will grow to $1.84 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to a rising aging population, rising healthcare expenditure, increasing prevalence of brain tumors, growing government initiatives, and a rise in the incidence and prevalence of high-grade gliomas. Major trends in the forecast period include advancements in imaging technologies, development of radiation therapies, introduction of chemotherapy regimens, clinical trials expansion, and the integration of immunotherapy.

The forecast of 5.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. neuro-oncology centers by driving up the cost of temozolomide and advanced MRI perfusion software sourced from Germany and Belgium, exacerbating brain tumor treatment costs and delaying precision medicine approaches. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of brain tumors is driving the growth of the low-grade glioma market. Brain tumors, abnormal growths of cells in the brain or surrounding tissues, can be benign or malignant. The rising occurrence of brain tumors is linked to factors such as radiation exposure, environmental pollutants, genetic predisposition, and aging. Low-grade glioma treatments utilize advanced diagnostic techniques and targeted therapies including surgery, radiation, and chemotherapy to slow tumor progression, preserve neurological function, and improve patient outcomes. Early detection and personalized treatment approaches are crucial for managing brain tumors with similar growth patterns. For instance, in October 2023, The Central Brain Tumor Registry of the United States (CBTRUS) reported that the worldwide incidence of primary malignant brain tumors in 2022 was approximately 3.5 per 100,000 people, with higher rates in high-income countries (4.9 per 100,000) compared to low-middle-income (2.4 per 100,000) and low-income countries. This increasing prevalence of brain tumors is propelling the expansion of the low-grade glioma market.

Leading companies in the low-grade glioma market are advancing treatment options by integrating combination therapies and targeted therapies, such as genetic alteration drugs, to improve patient outcomes. Genetic alteration drugs are designed to target and modify specific genetic mutations or abnormalities that drive uncontrolled cell growth, making them a promising approach for treating conditions such as low-grade glioma. For instance, in May 2024, Day One Biopharmaceuticals, a US-based biotechnology company, launched Tovorafenib (Ojemda) after receiving accelerated FDA approval. This targeted therapy is specifically designed for children aged six months and older with unresectable or recurrent low-grade glioma (LGG) characterized by BRAF gene alterations. It offers a convenient once-weekly oral treatment, addressing an urgent need for pediatric LGG patients with limited prior treatment options.

In July 2024, Ipsen Biopharmaceuticals Inc., a US-based pharmaceutical company, partnered with Day One Biopharmaceuticals Inc. to commercialize tovorafenib for pediatric low-grade glioma (pLGG) with BRAF mutations. This collaboration aims to expand global access to the treatment while leveraging Ipsen's oncology expertise and international reach to accelerate regulatory approvals and commercial efforts outside the United States. Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing targeted therapies for pediatric brain tumors, particularly low-grade glioma.

Major players in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, and Sunesis Pharmaceuticals Inc.

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in low-grade glioma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the low-grade glioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The low-grade glioma market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, and targeted therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The low-grade glioma market also includes sales of astrocytomas, oligodendrogliomas, and ependymomas. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Low-Grade Glioma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on low-grade glioma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for low-grade glioma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The low-grade glioma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Type: Trametinib; Dabrafenib; Ivosidenib; Mirdametinib
2) By Treatment: Surgery; Chemotherapy; Radiation
3) By Route Of Administration: Topical; Oral
4) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies
Companies Mentioned: McKesson Corporation; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; Daiichi Sankyo Company Limited; Ipsen S.A.; BeiGene Ltd.; NovoCure Limited; Les Laboratoires Servier; Day One Biopharmaceuticals Inc.; CStone Pharmaceuticals Co. Ltd.; AnHeart Therapeutics Inc.; Apollomics Inc.; Agios Pharmaceuticals Inc.; BioMed Valley Discoveries Inc.; Avistone Biotechnology Co. Ltd.; NextSource Biotechnology LLC; Sunesis Pharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34081u

1. Executive Summary

2. Low-Grade Glioma Market Characteristics

3. Low-Grade Glioma Market Trends And Strategies

4. Low-Grade Glioma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Low-Grade Glioma Growth Analysis And Strategic Analysis Framework

5.1. Global Low-Grade Glioma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Low-Grade Glioma Market Growth Rate Analysis
5.4. Global Low-Grade Glioma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Low-Grade Glioma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Low-Grade Glioma Total Addressable Market (TAM)

6. Low-Grade Glioma Market Segmentation

6.1. Global Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Trametinib
Dabrafenib
Ivosidenib
Mirdametinib
6.2. Global Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgery
Chemotherapy
Radiation
6.3. Global Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Topical
Oral
6.4. Global Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

7. Low-Grade Glioma Market Regional And Country Analysis

7.1. Global Low-Grade Glioma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Low-Grade Glioma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Low-Grade Glioma Market

8.1. Asia-Pacific Low-Grade Glioma Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Low-Grade Glioma Market

9.1. China Low-Grade Glioma Market Overview
9.2. China Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Low-Grade Glioma Market

10.1. India Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Low-Grade Glioma Market

11.1. Japan Low-Grade Glioma Market Overview
11.2. Japan Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Low-Grade Glioma Market

12.1. Australia Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Low-Grade Glioma Market

13.1. Indonesia Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Low-Grade Glioma Market

14.1. South Korea Low-Grade Glioma Market Overview
14.2. South Korea Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Low-Grade Glioma Market

15.1. Western Europe Low-Grade Glioma Market Overview
15.2. Western Europe Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Low-Grade Glioma Market

16.1. UK Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Low-Grade Glioma Market

17.1. Germany Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Low-Grade Glioma Market

18.1. France Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Low-Grade Glioma Market

19.1. Italy Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Low-Grade Glioma Market

20.1. Spain Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Low-Grade Glioma Market

21.1. Eastern Europe Low-Grade Glioma Market Overview
21.2. Eastern Europe Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Low-Grade Glioma Market

22.1. Russia Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Low-Grade Glioma Market

23.1. North America Low-Grade Glioma Market Overview
23.2. North America Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Low-Grade Glioma Market

24.1. USA Low-Grade Glioma Market Overview
24.2. USA Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Low-Grade Glioma Market

25.1. Canada Low-Grade Glioma Market Overview
25.2. Canada Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Low-Grade Glioma Market

26.1. South America Low-Grade Glioma Market Overview
26.2. South America Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Low-Grade Glioma Market

27.1. Brazil Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Low-Grade Glioma Market

28.1. Middle East Low-Grade Glioma Market Overview
28.2. Middle East Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Low-Grade Glioma Market

29.1. Africa Low-Grade Glioma Market Overview
29.2. Africa Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Low-Grade Glioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Low-Grade Glioma Market Competitive Landscape And Company Profiles

30.1. Low-Grade Glioma Market Competitive Landscape
30.2. Low-Grade Glioma Market Company Profiles
- 30.2.1. McKesson Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Low-Grade Glioma Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Daiichi Sankyo Company Limited
31.3. Ipsen S.A.
31.4. BeiGene Ltd.
31.5. NovoCure Limited
31.6. Les Laboratoires Servier
31.7. Day One Biopharmaceuticals Inc.
31.8. CStone Pharmaceuticals Co. Ltd.
31.9. AnHeart Therapeutics Inc.
31.10. Apollomics Inc.
31.11. Agios Pharmaceuticals Inc.
31.12. BioMed Valley Discoveries Inc.
31.13. Avistone Biotechnology Co. Ltd.
31.14. NextSource Biotechnology LLC
31.15. Sunesis Pharmaceuticals Inc.

32. Global Low-Grade Glioma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Low-Grade Glioma Market

34. Recent Developments In The Low-Grade Glioma Market

35. Low-Grade Glioma Market High Potential Countries, Segments and Strategies

35.1 Low-Grade Glioma Market In 2029 - Countries Offering Most New Opportunities
35.2 Low-Grade Glioma Market In 2029 - Segments Offering Most New Opportunities
35.3 Low-Grade Glioma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer